Literature DB >> 9596700

Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes.

C A Laferriere1, R K Sood, J M de Muys, F Michon, H J Jennings.   

Abstract

A simple and convenient method was developed for the preparation of Streptococcus pneumoniae type 14 polysaccharide (Pn14PS)-tetanus toxoid (TT) conjugate vaccines, using terminally linked Pn14PS fragments of different lengths. Native Pn14PS was simultaneously depolymerized and activated for conjugation by partial N-deacetylation followed by nitrous acid deamination which yielded fragments (1.4 to 150.0 kDa) having a free aldehyde at the reducing end. These were then conjugated to TT through their terminal aldehydic groups, using the reductive amination procedure. All of the above conjugates, when injected in rabbits, induced anti-Pn14PS antibodies, whereas the native Pn14PS did not. The amounts of anti-Pn14PS antibodies elicited by these conjugates, as determined by enzyme-linked immunosorbent assay, followed a trend with conjugates containing the highest-molecular-weight Pn14PS eliciting the highest titers. The same trend was also observed in the ability of the antibodies to opsonize and kill live type 14 pneumococci, although the increase in opsonophagocytic activity was more pronounced and did not correlate linearly with increases in antibody titer. Competitive inhibition of the binding of different conjugate antisera to the native Pn14PS, using Pn14PS fragments as inhibitors, established that the conjugates induced antibodies with specificities for different lengths of Pn14PS beginning at 2 repeating units (RU). It was also established, both immunologically and antigenically, that at least 4 RU of Pn14PS were required to form an extended conformational epitope and that approximately 22 RU of Pn14PS were required to duplicate the same epitope on the same saccharide chain. The conformational epitope was found to be essential for the induction of antibodies with high opsonophagocytic activity and that augmentation of opsonophagocytic activity was also dependent on further chain extension.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596700      PMCID: PMC108222          DOI: 10.1128/IAI.66.6.2441-2446.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  Structural studies on the specific type-14 pneumococcal polysaccharide.

Authors:  B Lindberg; J Lönngren; D A Powell
Journal:  Carbohydr Res       Date:  1977-09       Impact factor: 2.104

2.  Determinant specificities of the groups B and C polysaccharides of Neisseria meningitidis.

Authors:  H J Jennings; R Roy; F Michon
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

3.  Human adult immunogenicity of protein-coupled pneumococcal capsular antigens of serotypes prevalent in otitis media.

Authors:  P Anderson; R Betts
Journal:  Pediatr Infect Dis J       Date:  1989-01       Impact factor: 2.129

4.  NMR and molecular dynamics studies of the conformational epitope of the type III group B Streptococcus capsular polysaccharide and derivatives.

Authors:  J R Brisson; S Uhrinova; R J Woods; M van der Zwan; H C Jarrell; L C Paoletti; D L Kasper; H J Jennings
Journal:  Biochemistry       Date:  1997-03-18       Impact factor: 3.162

5.  Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates.

Authors:  A Fattom; W F Vann; S C Szu; A Sutton; X Li; D Bryla; G Schiffman; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

6.  Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.

Authors:  H J Jennings; C Lugowski
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

7.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

8.  A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharide.

Authors:  M R Wessels; A Muñoz; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

Review 9.  The role of complement in the host's defense against Streptococcus pneumoniae.

Authors:  J A Winkelstein
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

10.  Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide.

Authors:  M R Wessels; D L Kasper
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  20 in total

1.  Thermodynamics and density of binding of a panel of antibodies to high-molecular-weight capsular polysaccharides.

Authors:  Shannon L Harris; Philip Fernsten
Journal:  Clin Vaccine Immunol       Date:  2008-11-12

2.  Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice.

Authors:  W T Jansen; S Hogenboom; M J Thijssen; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

3.  Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.

Authors:  Francis Michon; Catherine Uitz; Arun Sarkar; Anello J D'Ambra; Maryline Laude-Sharp; Samuel Moore; Peter C Fusco
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Opsonic antibodies to Enterococcus faecalis strain 12030 are directed against lipoteichoic acid.

Authors:  Christian Theilacker; Zbigniew Kaczynski; Andrea Kropec; Francesca Fabretti; Tatjana Sange; Otto Holst; Johannes Huebner
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

5.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

6.  Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.

Authors:  Dodi Safari; Huberta A T Dekker; John A F Joosten; Dirk Michalik; Adriana Carvalho de Souza; Roberto Adamo; Martina Lahmann; Andreas Sundgren; Stefan Oscarson; Johannis P Kamerling; Harm Snippe
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

7.  Structures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibody.

Authors:  B Vulliez-Le Normand; F A Saul; A Phalipon; F Bélot; C Guerreiro; L A Mulard; G A Bentley
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-10       Impact factor: 11.205

8.  Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Gil Ben-Menachem; Vince Pozsgay; John B Robbins; Rachel Schneerson
Journal:  Vaccine       Date:  2008-05-20       Impact factor: 3.641

9.  Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.

Authors:  Christian Theilacker; Fadie T Coleman; Simone Mueschenborn; Nicolas Llosa; Martha Grout; Gerald B Pier
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

10.  Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.

Authors:  Fatme Mawas; Jutta Niggemann; Christopher Jones; Michael J Corbel; Johannis P Kamerling; Johannes F G Vliegenthart
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.